grant
First in Human Trials of ProAgio, a Cytotoxin
Organization DIVISION OF BASIC SCIENCES - NCILocation UNITED STATES
NIHUS FederalResearch GrantFY2025Angiogenesis AntagonistsAngiogenesis BlockersAngiogenesis InhibitorsAngiogenetic AntagonistsAngiogenetic InhibitorsAngiogenic AntagonistsAngiogenic InhibitorsAngiostatic AgentsAnimal ModelAnimal Models and Related StudiesAnti-Angiogenetic AgentsAnti-Angiogenic AgentsAnti-Angiogenic DrugsAntiangiogenesis AgentsAntiangiogenic AgentsAntiangiogenic DrugsClinical ResearchClinical StudyCombined Modality TherapyCytotoxinDataDoseDrug toxicityDrugsEXTMRElementsEndothelial CellsEnrollmentExtramuralExtramural ActivitiesFibroblastsGeneralized GrowthGrowthHumanIntegrin aVBeta3Integrin alpha-v beta-3Integrin alphaVbeta3Integrin αVβ3KPC genetically-engineered mouseKPC modelKPC mouseKPC murineLSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-CreLSL-KrasG12D/+;LSL-p53R172H/+;Pdx-1-CreMacrophageManuscriptsMedicationMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsModern ManMultimodal TherapyMultimodal TreatmentMurineMusMφNeoplasm MetastasisNeovascularization InhibitorsPancreas Ductal AdenocarcinomaPancreas NeoplasmsPancreas TumorPancreatic Ductal AdenocarcinomaPancreatic TumorPatientsPharmaceutical PreparationsPreparationProtein EngineeringSafetySamplingSecondary NeoplasmSecondary TumorStable DiseaseTestingTherapeuticTissue GrowthWorkaVBeta3alpha-v beta-3 Integrin Receptorsantiangiogeniccancer metastasiscancer microenvironmentcell killingcombination therapycombined modality treatmentcombined treatmentdrug/agentenrollexperiencefirst in manfirst-in-humangenetic protein engineeringimproved outcomemodel of animalmulti-modal therapymulti-modal treatmentnovelontogenypancreatic neoplasiapancreatic neoplasmpre-clinical studypreclinical studypreparationsprotein designrational designresistance to therapyresistant to therapytherapeutic resistancetherapy resistanttreatment resistancetumortumor cell metastasistumor microenvironment
Description preview
Enrollment to the ProAgio study was completed this year and data are currently under analysis, including scientific correlatives being performed on patient samples. We have identified a safe dose of ProAgio to give to patients and found that several patients receiving the preferred dose experienced prolonged stable disease with little to no drug…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click